Evidence map›Paper›PMID 42768048›Full record

ArticleNature communications2026

Combinatorial targeting of the miR-379/miR-410 cluster normalizes glucose and lipid homeostasis in male models of diabetes and obesity.

Manuel Gil-Lozano, Estefanía Simoes, Moya Wu, Tobias Wiedemann, Yun Kwon, Revathi Sekar, Pauline Morigny, Maria Troullinaki, Juliane Merl-Pham, Michael Buettner and 17 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Manuel Gil-LozanoInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Estefanía SimoesInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Moya WuInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Tobias WiedemannInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-8101-7407
Yun KwonInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Revathi SekarInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Pauline MorignyInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-8001-7069
Maria TroullinakiInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Juliane Merl-PhamMetabolomics and Proteomics Core, Helmholtz Munich, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-3422-4083
Michael BuettnerMetabolomics Core Technology Platform, University of Heidelberg, Heidelberg, Germany.
Annette FeuchtingerCore Facility Pathology and Tissue Analytics, Helmholtz Munich, Neuherberg, Germany.
Celine JouffeInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-7176-4724
Adriano MaidaInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Daniela HassInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Daniel SamagaInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Gretchen WolffInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Juliano MachadoInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Maude GiroudInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Katarina KlepacInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Carolyn L CumminsDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, Canada.ORCID http://orcid.org/0000-0001-7603-6577
Marcos Ríos GarcíaInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Peter WeberInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.
Anja ZeigererInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.ORCID http://orcid.org/0000-0003-4072-0566
N Henriette UhlenhautGerman Center for Diabetes Research (DZD), Neuherberg, Germany.ORCID http://orcid.org/0000-0002-4220-4779
Julia SzendroediInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-7296-7152
Matthias BlüherGerman Center for Diabetes Research (DZD), Neuherberg, Germany.ORCID http://orcid.org/0000-0003-0208-2065
Stephan HerzigInstitute for Diabetes and Cancer, Helmholtz Munich, Neuherberg, Germany. stephan.herzig@helmholtz-munich.de.ORCID http://orcid.org/0000-0003-3950-3652

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 03VPO08920/ MIRANDABundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 16GW0195KBundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 16LW0116kBundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) DZHK Site project 81Z0600103Deutsche Forschungsgemeinschaft (German Research Foundation) TRR333Deutsche Forschungsgemeinschaft (German Research Foundation) ZE1037/1-3European Foundation for the Study of Diabetes (EFSD) 01KU1501CGouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) MOP-125900, PJT-156194
6 · The paper itself

Abstract

Non-coding RNAs from the Dlk1-Dio3 locus are critical for the maturation of metabolic tissues in early stages of postnatal development; however, their role in the mature organs remains elusive. Herein, we show that microRNAs from the miR-379/miR-410 cluster are robustly upregulated in livers of subjects with obesity and various mouse models of metabolic dysfunction. Adult-onset, combinatorial inhibition of this miRNA cluster by hepatocyte-specific expression of a decoy sequence reduces triglyceride, total and LDL cholesterol circulating levels, decreases basal glycemia and improves glucose tolerance and insulin sensitivity irrespective of sex. Consistent with the decoy-triggered enhancement of PI3K/mTOR signaling in these mice, hepatocytes expressing the combinatorial decoy show augmented mitochondrial mass and function. Notably, decoy therapy also ameliorates glucose and lipid homeostasis in both type 1 diabetic and diet-induced, type 2 pre-diabetic, obese male animals. Collectively, our results demonstrate that microRNAs from the miR-379/miR-410 cluster are critical regulators of metabolic homeostasis in the mature liver. Given the preservation of miRNA dysfunction in human obesity, hepatocyte-specific combinatorial inhibition of a large miRNA cluster represents an approach towards multi-parameter improvements in diabetes and obesity.

Indexed as

GlucoseLipid MetabolismMicroRNAsObesityAnimalsDisease Models, AnimalFemaleHepatocytesHomeostasisHumansInsulin ResistanceLiverMaleMiceMice, Inbred C57BLSignal TransductionGlucoseMicroRNAsMIRN379 microRNA, human

Identifiers

PMID42768048
PMCPMC13594115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.